Proteosys AG
Records under this name other than patents Proteosys AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,350,269 | Method of Effecting Neuroprotection Using Soluble Neuregulin Isoforms Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,813,978 | Method of Effecting Neuroprotection Using Soluble Neuregulin Isoforms Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,251,423 | Method of Effecting Neuroprotection Using Soluble Neuregulin Isoforms Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 7,824,923 | Neuregulin-β isoforms associated with neuronal processes Formerly held Term ended Term ended Dec 16, 2022 · From the USPTO record | Term ended | Term ended Dec 16, 2022 | From the USPTO record |
| US 7,919,582 | Neuregulin-β isoform Formerly held Term ended Ended no later than Feb 9, 2021 · From the USPTO record | Term ended | Ended no later than Feb 9, 2021 | From the USPTO record |
| US 8,466,144 | Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents Lapsed on the fee record Ended Jun 18, 2017 · From the USPTO record | Lapsed on the fee record | Ended Jun 18, 2017 | From the USPTO record |
| US 7,538,197 | Use of neuregulin-β as an indicator and/or target Formerly held Lapsed on the fee record Ended May 26, 2017 · From the USPTO record | Lapsed on the fee record | Ended May 26, 2017 | From the USPTO record |
| US 8,409,812 | Annexin A3 for Cancer Diagnosis Lapsed on the fee record Ended Apr 2, 2017 · High confidence | Lapsed on the fee record | Ended Apr 2, 2017 | High confidence |
| US 8,377,648 | Autoimmune regulation of prostate cancer by annexin A3 Lapsed on the fee record Ended Feb 19, 2017 · From the USPTO record | Lapsed on the fee record | Ended Feb 19, 2017 | From the USPTO record |
| US 8,039,464 | Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases Lapsed on the fee record Ended Oct 18, 2015 · From the USPTO record | Lapsed on the fee record | Ended Oct 18, 2015 | From the USPTO record |